Fig. 2From: FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCIPrediction model involving independent risk factors for 2-year ISR risk. FGF-23 fibroblast growth factor 23, ISR in-stent restenosis, PCI percutaneous coronary intervention, DES drug-eluting stent, CHD coronary heart disease, AUC area under the curve, CI confidence intervalBack to article page